|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
Posted on: 10/27/2009, by Barbara Belardi
Robert Gibbs, professor of pharmaceutical sciences, received a grant award from the University's Central Research Development Fund for "Effects of a Selective GPR30 Agonist Cholinergic Function in the Brain." This project will test the hypothesis that G-1, a selective GPR30 agonist, can enhance the function of cholinergic projections to the hippocampus similar to estradiol. The project also will develop siRNAs to knock-down GPR30 expression in specific regions of the brain, which will enable the evaluation of the role of GRP30 in mediating effects of estradiol and G-1 on cholinergic function and cognitive performance.